| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 424B5 | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| EFFECT | EFFECT |
Other
|
||
| S-3 | Simplified registration form |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% |
Other
|
||
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
